New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
04:55 EDTCRME, CRME, ALR, ALR, GALE, GALE, BIND, BIND, AVNR, AVNR, OCRX, OCRX, ONVO, ONVO, OSIR, OSIR, SGNT, SGNT, SNTA, SNTA, CRIS, CRISJMP Securities to hold a conference
Healthcare Conference to be held in New York on June 24-25.
News For CRME;SNTA;SGNT;OSIR;ONVO;OCRX;AVNR;BIND;GALE;ALR;CRIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
08:11 EDTCRISCuris 21.8M share Spot Secondary priced at $2.75
Cowen and RBC Capital acted as joint book running managers for the offering.
February 24, 2015
16:13 EDTCRISCuris reports Q EPS (7c), consensus (7c)
Subscribe for More Information
16:03 EDTCRISCuris files to sell common stock, no amount given
Subscribe for More Information
February 23, 2015
11:20 EDTSGNTSagent Pharmaceuticals initiates voluntary recall of Atracurium Besylate
Sagent Pharmaceuticals announced the voluntary nationwide recall of two lots of Atracurium Besylate Injection, USP, 50mg/5mL single-dose vials and four lots of Atracurium Besylate Injection, USP, 100mg/10mL multi-dose vials manufactured by Emcure Pharmaceuticals Ltd. and distributed by Sagent. Sagent has initiated this voluntary recall of Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL to the user level due to FDA observations pertaining to aseptic and GMP practices at the manufacturer's site potentially impacting product sterility. Non-sterility of a drug administered via the intravenous route has the potential to result in infections, which could be fatal, especially in patients who are immunocompromised. Sagent has transferred the manufacture of this product to its own facility and this product manufactured at the Sagent facility will not be impacted by the recall. Sagent is not aware of any adverse patient events resulting from the use of the subject product lots. The lot numbers being recalled are VATA012, VATA015 and VATB012, VATB013, VATB014, VATB017 which were distributed to hospitals, wholesalers and distributors nationwide from February 2014 through February 2015. Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation, and is supplied in single-dose and multi-dose vials.
February 20, 2015
11:46 EDTSNTASynta Pharmaceuticals management to meet with Jefferies
Subscribe for More Information
February 19, 2015
09:12 EDTOCRXOn The Fly: Pre-market Movers
Subscribe for More Information
07:05 EDTSGNTSagent Pharmaceuticals sees FY15 revenue $325M-$375M, consensus $343.29M
Subscribe for More Information
07:04 EDTSGNTSagent Pharmaceuticals reports Q4 EPS 94c, may not compare to consensus 1c
Subscribe for More Information
February 18, 2015
16:34 EDTOCRXOcera Therapeutics reports OCR-002 Phase 2a topline results
Subscribe for More Information
February 17, 2015
10:56 EDTALRScopia Capital reports 6.47% passive stake in Alere
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use